{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:14:14Z","timestamp":1790734454933,"version":"4.1.0"},"reference-count":68,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Inhibitors of the IL-6 signaling pathway, such as tocilizumab, are frequently administered for the treatment of immune diseases, e.g., rheumatoid arthritis and multicentric Castleman\u2019s disease. The aim of this systematic review and meta-analysis was to ascertain the effects of IL-6 pathway inhibitors on weight and body mass index (BMI). Using PRISMA guidelines, we systematically reviewed relevant articles from three databases (PubMed, OVID, EMBASE). A random effects model was used to estimate standardized mean change (SMCC). Ten studies with a total of 1531 patients were included in the meta-analysis for weight and ten studies with a total of 1537 patients were included in the BMI meta-analysis. The most commonly administered IL-6 pathway inhibitor was tocilizumab. IL-6 pathway inhibitors were associated with increases in weight (SMCC = 0.09, p = 0.016, 95% CI [0.03, 0.14]) and BMI (SMCC = 0.10, p = 0.0001, 95% CI [0.05, 0.15]). These findings suggest that the IL-6 pathway is involved in weight regulation. Modulating IL-6 signaling may be a potential future therapeutic avenue used as an adjunct for the treatment of disorders associated with weight changes, such as cancer cachexia and anorexia nervosa.<\/jats:p>","DOI":"10.3390\/ijms21176290","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T08:11:19Z","timestamp":1598861479000},"page":"6290","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Effects of IL-6 Signaling Pathway Inhibition on Weight and BMI: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7867-5110","authenticated-orcid":false,"given":"Olivia","family":"Patsalos","sequence":"first","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College London, London SE5 8AF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethan","family":"Dalton","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College London, London SE5 8AF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1209-6073","authenticated-orcid":false,"given":"Hubertus","family":"Himmerich","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology &amp; Neuroscience, King\u2019s College London, London SE5 8AF, UK"},{"name":"South London and Maudsley NHS Foundation Trust, London SE5 8AZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.2337\/diabetes.54.suppl_2.S114","article-title":"Interleukin-6 and Diabetes: The good, the bad, or the indifferent?","volume":"54","author":"Kristiansen","year":"2005","journal-title":"Diabetes"},{"key":"ref_2","first-page":"291","article-title":"The role of interleukin-6 in development and progression of atherosclerosis","volume":"22","author":"Zdrojewicz","year":"2007","journal-title":"Polski Merkur. Lek. Organ Polskiego Towar. Lek."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","article-title":"A meta-analysis of cytokines in major depression","volume":"67","author":"Dowlati","year":"2010","journal-title":"Boil. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/annrheumdis-2012-202470","article-title":"Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: Systematic literature review and meta-analysis informing a consensus statement","volume":"72","author":"Schoels","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hoc.2017.09.003","article-title":"The role of interleukin-6 in castleman disease","volume":"32","author":"Yoshizaki","year":"2018","journal-title":"Hematol. Clin. N. Am."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol. Nat. Publ. Group"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.biopha.2018.09.177","article-title":"The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer","volume":"108","author":"Masjedi","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.7150\/ijbs.4614","article-title":"Interleukin-6\u2014A Key Regulator of Colorectal Cancer Development","volume":"8","author":"Waldner","year":"2012","journal-title":"Int. J. Boil. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/SPC.0000000000000091","article-title":"Role of interleukin-6 in cachexia","volume":"8","author":"Narsale","year":"2014","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/bjc.1996.294","article-title":"The relationship between weight loss and interleukin 6 in non-small-cell lung cancer","volume":"73","author":"Scott","year":"1996","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S0306-4522(02)00447-5","article-title":"Induction of uncoupling protein 1 by central interleukin-6 gene delivery is dependent on sympathetic innervation of brown adipose tissue and underlies one mechanism of body weight reduction in rats","volume":"115","author":"Li","year":"2002","journal-title":"Neuroscience"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbi.2009.09.002","article-title":"Transgenic mice with astrocyte-targeted production of interleukin-6 are resistant to high-fat diet-induced increases in body weight and body fat","volume":"24","author":"Hidalgo","year":"2010","journal-title":"Brain Behav. Immun."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2826.2011.02158.x","article-title":"Interleukin-6 regulates the expression of hypothalamic neuropeptides involved in body weight in a gender-dependent way","volume":"23","author":"Trujillo","year":"2011","journal-title":"J. Neuroendocr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.bbadis.2015.01.017","article-title":"Interleukin-6 gene transfer reverses body weight gain and fatty liver in obese mice","volume":"1852","author":"Ma","year":"2015","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Basis Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nm0102-75","article-title":"Interleukin-6-deficient mice develop mature-onset obesity","volume":"8","author":"Wallenius","year":"2002","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R393","DOI":"10.1152\/ajpregu.00716.2007","article-title":"Interleukin-6 and cachexia inApcMin\/+mice","volume":"294","author":"Baltgalvis","year":"2008","journal-title":"Am. J. Physiol. Integr. Comp. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/JES.0b013e3181f44f11","article-title":"Interleukin 6 as a Key Regulator of Muscle Mass during Cachexia","volume":"38","author":"Carson","year":"2010","journal-title":"Exerc. Sport Sci. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/0006-3223(94)90594-0","article-title":"Role of interleukin-6 and transforming growth factor-\u03b2 in anorexia nervosa","volume":"36","author":"Pomeroy","year":"1994","journal-title":"Boil. Psychiatry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpsychires.2018.06.002","article-title":"A meta-analysis of cytokine concentrations in eating disorders","volume":"103","author":"Dalton","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.7678183","article-title":"Adipose expression of tumor necrosis factor-\u03b1: Direct role in obesity-linked insulin resistance","volume":"259","author":"Hotamisligil","year":"1993","journal-title":"Science"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/21623945.2018.1493901","article-title":"The role of adipocyte-specific IL-6-type cytokine signaling in FFA and leptin release","volume":"7","author":"Wueest","year":"2018","journal-title":"Adipocyte"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Schmidt, F.M., Weschenfelder, J., Sander, C., Minkwitz, J., Thormann, J., Chittka, T., Mergl, R., Kirkby, K.C., Fa\u00dfhauer, M., and Stumvoll, M. (2015). Inflammatory cytokines in general and central obesity and modulating effects of physical activity. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121971"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/jcsm.12189","article-title":"Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis","volume":"8","author":"Tournadre","year":"2017","journal-title":"J. Cachex Sarcopenia Muscle"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cyto.2012.11.007","article-title":"Weight change during pharmacological blockade of interleukin-6 or tumor necrosis factor-\u03b1 in patients with inflammatory rheumatic disorders: A 16-week comparative study","volume":"61","author":"Younis","year":"2013","journal-title":"Cytokine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/a-0833-4627","article-title":"Effect of IL-6 receptor blockade on proprotein convertase subtilisin\/kexin type-9 and cholesterol efflux capacity in rheumatoid arthritis patients","volume":"51","author":"Machado","year":"2019","journal-title":"Horm. Metab. Res."},{"key":"ref_26","first-page":"293","article-title":"Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: Potential cardiovascular protective role of IL-6 inhibition","volume":"37","author":"Fioravanti","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hoffman, E., Rahat, M.A., Feld, J., Elias, M., Rosner, I., Kaly, L., Lavi, I., Gazitt, T., and Zisman, D. (2019). Effects of tocilizumab, an anti-interleukin-6 receptor antibody, on serum lipid and adipokine levels in patients with rheumatoid arthritis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20184633"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti\u2013interleukin-6 receptor antibody treatment of multicentric castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Pappas, D.A., Etzel, C.J., Crabtree, M., Blachley, T., Best, J., Zlotnick, S., and Kremer, J.M. (2020). Effectiveness of tocilizumab in patients with rheumatoid arthritis is unaffected by comorbidity burden or obesity: Data from a US registry. J. Rheumatol.","DOI":"10.3899\/jrheum.190282"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3899\/jrheum.140673","article-title":"Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient","volume":"42","author":"Pers","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_31","first-page":"1199","article-title":"SAT0702 Influence of obesity and gender on drug effectiveness in rheumatoid arthritis depends on the outcome considered","volume":"77","author":"Meissner","year":"2018","journal-title":"An. Rheum. Dis"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.cmet.2018.12.007","article-title":"Exercise-induced changes in visceral adipose tissue mass are regulated by Il-6 signaling: A randomized controlled TRIAL","volume":"29","author":"Christensen","year":"2019","journal-title":"Cell Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10067-014-2704-1","article-title":"Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade","volume":"34","author":"Makrilakis","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Patsalos, O., Dalton, B., Leppanen, J., Ibrahim, M.A.A., and Himmerich, H. (2020). Impact of TNF-\u03b1 inhibitors on body weight and bmi: A systematic review and meta-analysis. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00481"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/rheumatology\/kez535","article-title":"Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis","volume":"59","author":"Kekow","year":"2020","journal-title":"Rheumatology"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Bonetto, A., Aydo\u011fdu, T., Kunzevitzky, N.J., Guttridge, D.C., Khuri, S., Koniaris, L.G., and Zimmers, T.A. (2011). STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0022538"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: Mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Tsoli, M., Schweiger, M., Vanniasinghe, A.S., Painter, A., Zechner, R., Clarke, S., and Robertson, G. (2014). Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092966"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1158\/0008-5472.CAN-15-3152","article-title":"Differential effects of interleukin-6 and activin A in the development of cancer-associated cachexia","volume":"76","author":"Chen","year":"2016","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.celrep.2017.03.043","article-title":"IL-6 improves energy and glucose homeostasis in obesity via enhanced central IL-6 trans\u2014Signaling","volume":"19","author":"Timper","year":"2017","journal-title":"Cell Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/j.celrep.2019.02.044","article-title":"Parabrachial interleukin-6 reduces body weight and food intake and increases thermogenesis to regulate energy metabolism","volume":"26","author":"Mishra","year":"2019","journal-title":"Cell Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e000398","DOI":"10.3945\/cdn.116.000398","article-title":"Decreased appetite after high-intensity exercise correlates with increased plasma interleukin-6 in normal-weight and overweight\/obese boys","volume":"1","author":"Hunschede","year":"2017","journal-title":"Curr. Dev. Nutr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood.V84.8.2472.2472","article-title":"Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: Effect on lymphoma growth and on B clinical symptoms","volume":"84","author":"Emilie","year":"1994","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1139\/apnm-2018-0019","article-title":"The role of IL-6 in exercise-induced anorexia in normal-weight boys","volume":"43","author":"Hunschede","year":"2018","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00125-004-1403-x","article-title":"Interleukin-6 and tumor necrosis factor-\u03b1 are not increased in patients with Type 2 diabetes: Evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness","volume":"47","author":"Carey","year":"2004","journal-title":"Diabetologia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1210\/me.2005-0490","article-title":"Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle","volume":"20","author":"Bouzakri","year":"2006","journal-title":"Mol. Endocrinol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.2337\/diabetes.53.4.1060","article-title":"Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo","volume":"53","author":"Kim","year":"2004","journal-title":"Diabetes"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.2337\/db05-1404","article-title":"Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via amp-activated protein kinase","volume":"55","author":"Carey","year":"2006","journal-title":"Diabetes"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1152\/physrev.90100.2007","article-title":"Muscle as an endocrine organ: Focus on muscle-derived interleukin-6","volume":"88","author":"Pedersen","year":"2008","journal-title":"Physiol. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1023\/A:1026070911202","article-title":"Searching for the exercise factor: Is IL-6 a candidate?","volume":"24","author":"Pedersen","year":"2003","journal-title":"J. Muscle Res. Cell Motil."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1152\/jappl.1988.64.5.1942","article-title":"Effects of exercise and lack of exercise on insulin sensitivity and responsiveness","volume":"64","author":"King","year":"1988","journal-title":"J. Appl. Physiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4093\/dmj.2016.40.4.253","article-title":"The effect of regular exercise on insulin sensitivity in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"40","author":"Way","year":"2016","journal-title":"Diabetes Metab. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1385\/ENDO:29:1:109","article-title":"Epidemiology, trends, and morbidities of obesity and the metabolic syndrome","volume":"29","author":"Bray","year":"2006","journal-title":"Endocrine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome","volume":"109","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/archgenpsychiatry.2010.2","article-title":"Overweight, obesity, and depression","volume":"67","author":"Luppino","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/17512433.2018.1383895","article-title":"Psychopharmacological advances in eating disorders","volume":"11","author":"Himmerich","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Himmerich, H., Bentley, J., Kan, C., and Treasure, J. (2019). Genetic risk factors for eating disorders: An update and insights into pathophysiology. Ther. Adv. Psychopharmacol., 9.","DOI":"10.1177\/2045125318814734"},{"key":"ref_59","unstructured":"Feingold, K.R., Anawalt, B., and Boyce, A. (2019). Drugs that Affect Body Weight, Body Fat Distribution and Metabolism."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and Group, T.P. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_61","unstructured":"(2019, April 08). Study Quality Assessment Tools|National Heart, Lung, and Blood Institute (NHLBI), Available online: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"ref_62","unstructured":"R Core Team (2015). R. A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses inRwith themetaforPackage","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1348\/000711000159150","article-title":"Distribution of the standardized mean change effect size for meta-analysis on repeated measures","volume":"53","author":"Morris","year":"2000","journal-title":"Br. J. Math. Stat. Psychol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"600","DOI":"10.22237\/jmasm\/1257035160","article-title":"Estimation of the standardized mean difference for repeated measures designs","volume":"8","author":"Smith","year":"2009","journal-title":"J. Mod. Appl. Stat. Methods"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/00401706.1977.10489493","article-title":"Detection of influential observation in linear regression","volume":"19","author":"Cook","year":"1977","journal-title":"Technometrics"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","article-title":"A power primer","volume":"112","author":"Cohen","year":"1992","journal-title":"Psychol Bull."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/17\/6290\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:04:56Z","timestamp":1760177096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/17\/6290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":68,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["ijms21176290"],"URL":"https:\/\/doi.org\/10.3390\/ijms21176290","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]}}}